SPRIND - Bundesagentur für Sprunginnovationen hat dies direkt geteilt
We're excited to announce that AATec Medical has secured EUR 4 million in pre-Series A funding from Germany’s Federal Agency for Disruptive Innovation SPRIND - Bundesagentur für Sprunginnovationen, along with support from private investors, industry experts, and single family offices. This investment will advance IND-enabling activities for our lead drug candidate ATL-105 for entry into clinical development by 2026. The first target indication is non-cystic fibrosis bronchiectasis (NCFB) - a chronic inflammatory respiratory disease affecting millions and currently lacking causative treatment options. ATL-105 is based on a novel recombinant version of alpha-1 antitrypsin delivered directly to the lungs through AATec’s protein inhalation approach - maximizing therapeutic effects at the primary site of inflammation while minimizing systemic side effects. AATec develops ATL-105 as a platform for several respiratory diseases of high medical need. “At SPRIND, we're looking for ideas that can fundamentally change things for the better. We believe that AATec’s approach using recombinant alpha-1 antitrypsin has great potential in a wide range of respiratory diseases and infections. Innovations like this can be key in protecting public health and strengthening the resilience of our healthcare systems.” – Sigrid Koeth, Innovation Manager at SPRIND 🔗 Read the full press release here: https://lnkd.in/dMqhMbCH #respiratoryhealth #innovation #publichealth #clinicaldevelopment #NCFB